Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses

Journal of Immunology

Volumn 182, Issue 3, 2009, Pages 1541-1547

  Maier, Lisa M ^a,b   Anderson, David E ^a   Severson, Christopher A ^a   Baecher Allan, Clare ^a   Healy, Brian ^a   Liu, David V ^c   Wittrup, K Dane ^c   De Jager, Philip L ^a,b,d   Hafler, David A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d LABORATORY FOR MOLECULAR MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; ALLELE; ARTICLE; AUTOIMMUNE DISEASE; CELL EXPANSION; CHRONIC INFLAMMATION; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ADOLESCENT; AGED; BIOSYNTHESIS; BLOOD; CELL CULTURE; COMPARATIVE STUDY; DRUG ANTAGONISM; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

ADOLESCENT; ADULT; AGED; CELLS, CULTURED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 63149109244     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.3.1541     Document Type: Article

References (35)

1. Hafler, D. A., J. M. Slavik, D. E. Anderson, K. C. O'Connor, P. De Jager, and C. Baecher-Allan. 2005. Multiple sclerosis. Immunol. Rev. 204: 208-231.
2. Hafler, D. A., D. A. Fox, M. E. Manning, S. F. Schlossmann, E. L. Reinherz, and H. L. Weiner. 1985. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N. Engl. J. Med. 312: 1405-1411.
3. 1 integrin. Nature 356: 63-66.
4. Greenberg, S. J., L. Marcon, B. J. Hurwitz, T. A. Waldmann, and D. L. Nelson. 1988. Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. N. Engl. J. Med. 319: 1019-1020.
5. Gallo, P., M. G. Piccinno, S. Pagni, V. Argentiero, B. Giometto, F. Bozza, and B. Tavolato. 1989. Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and γ-IFN levels in serum and cerebrospinal fluid. J. Neurol. Sci. 92: 9-15.
6. Trapp, B. D., R. Ransohoff, and R. Rudick. 1999. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12: 295-302.
7. Hauser, S. L., and J. R. Oksenberg. 2006. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52: 61-76.
8. The International Multiple Sclerosis Genetics Consortium. 2007. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357: 851-862.
9. Lowe, C. E., J. D. Cooper, T. Brusko, N. M. Walker, D. J. Smyth, R. Bailey, K. Bourget, V. Plagnol, S. Field, M. Atkinson, et al. 2007. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat. Genet. 39: 1074-1082.
10. Brand, O. J., C. E. Lowe, J. M. Heward, J. A. Franklyn, J. D. Cooper, J. A. Todd, and S. C. Gough. 2007. Association of the interleukin-2 receptor α (IL-2Rα)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin. Endocrinol. 66: 508-512.
11. Malek, T. R., and A. L. Bayer. 2004. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4: 665-674.
12. Robb, R. J., and R. M. Kutny. 1987. Structure-function relationships for the IL 2-receptor system, IV: analysis of the sequence and ligand-binding properties of soluble Tac protein. J. Immunol. 139: 855-862.
13. Rubin, L. A., F. Galli, W. C. Greene, D. L. Nelson, and G. Jay. 1990. The molecular basis for the generation of the human soluble interleukin 2 receptor. Cytokine 2: 330-336.
14. Kim, H. P., J. Imbert, and W. J. Leonard. 2006. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev. 17: 349-366.
15. Makis, A. C., E. Galanakis, E. C. Hatzimichael, Z. L. Papadopoulou, A. Siamopoulou, and K. L. Bourantas. 2005. Serum levels of soluble interleukin-2 receptor α(sIL-2Rα) as a predictor of outcome in brucellosis. J. Infect. 51: 206-210.
16. Giordano, C., A. Galluzzo, A. Marco, F. Panto, M. P. Amato, C. Caruso, and G. D. Bompiani. 1988. Increased soluble interleukin-2 receptor levels in the sera of type 1 diabetic patients. Diabetes Res. 8: 135-138.
17. Adachi, K., T. Kumamoto, and S. Araki. 1989. Interleukin-2 receptor levels indicating relapse in multiple sclerosis. Lancet 1: 559-560.
18. Rose-John, S., and P. C. Heinrich. 1994. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 300(Pt. 2): 281-290.
19. Rubinstein, M. P., M. Kovar, J. F. Purton, J. H. Cho, O. Boyman, C. D. Surh, and J. Sprent. 2006. Converting IL-15 to a superagonist by binding to soluble IL-15Rα. Proc. Natl. Acad. Sci. USA 103: 9166-9171.
20. Jones, S. A., S. Horiuchi, N. Topley, N. Yamamoto, and G. M. Fuller. 2001. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 15: 43-58.
21. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212: 8-27.
22. McDonald, W. I., A. Compston, G. Edan, D. Goodkin, H. P. Hartung, F. D. Lublin, H. F. McFarland, D. W. Paty, C. H. Polman, S. C. Reingold, et al. 2001. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50: 121-127.
23. Miller, D., F. Barkhof, X. Montalban, A. Thompson, and M. Filippi. 2005. Clinically isolated syndromes suggestive of multiple sclerosis: II. Non-conventional MRI, recovery processes, and management. Lancet Neurol. 4: 341-348.
24. Maier, L. M., D. E. Anderson, P. L. De Jager, L. S. Wicker, and D. A. Hafler. 2007. Allelic variant in CTLA4 alters T cell phosphorylation patterns. Proc. Natl. Acad. Sci. USA 104: 18607-18612.
25. Leonard, W. J., and J. J. O'Shea. 1998. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16: 293-322.
26. Waldmann, T. A. 2006. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6: 595-601.
27. Freedman, M. S., K. L. Muth, J. L. Trotter, C. N. Yoshizawa, and J. P. Antel. 1992. Prospective serial analysis of interleukin-2 and soluble interleukin-2 receptor in relapsing-remitting multiple sclerosis. Neurology 42: 1596-1601.
28. Rubin, L. A., C. C. Kurman, M. E. Fritz, W. E. Biddison, B. Boutin, R. Yarchoan, and D. L. Nelson. 1985. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 135: 3172-3177.
29. Kniep, E. M., I. Strelow, and M. L. Lohmann-Matthes. 1992. The monocyte interleukin-2 receptor light chain: production of cell-associated and soluble interleukin-2 receptor by monocytes. Immunology 75: 299-304.
30. Holter, W., C. K. Goldman, L. Casabo, D. L. Nelson, W. C. Greene, and T. A. Waldmann. 1987. Expression of functional IL 2 receptors by lipopolysaccharide and interferon-γ stimulated human monocytes. J. Immunol. 138: 2917-2922.
31. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199: 971-979.
32. Gong, D., and T. R. Malek. 2007. Cytokine-dependent Blimp-1 expression in activated T cells inhibits IL-2 production. J. Immunol. 178: 242-252.
33. Villarino, A. V., C. M. Tato, J. S. Stumhofer, Z. Yao, Y. K. Cui, L. Hennighausen, J. J. O'Shea, and C. A. Hunter. 2007. Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. J. Exp. Med. 204: 65-71.
34. Liu, D. V., L. M. Maier, D. A. Hafler, and K. D. Wittrup. Engineered interleukin-2 antagonists for inhibition of regulatory T cells. Submitted for publication.
35. Maier, L. M., C. E. Lowe, J. Cooper, K. Downes, D. E. Anderson, C. Severson, P. M. Clark, B. Healy, N. Walker, C. Aubin, et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genetics In press.